Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
|Articles|June 22, 2012
VIDEO: Louis Burns Talks About Lowering Cost Technology to Improve Patient Care
Innovation in healthcare is becoming more important as the environment continues to evolve. There are a couple key components to increasing the adoption rate of new technologies and ideas in healthcare, according to Burns.
Advertisement
Innovation in healthcare is becoming more important as the environment continues to evolve. There are a couple key components to increasing the adoption rate of new technologies and ideas in healthcare, according to Burns.
“The industry needs to quit holding on so hard to the past. Change is something they’re adverse to and they’ve got to get a little more risk adverse and start moving forward,” says Burns.
This video interview was performed on June 21, 2012, at the America's Health Insurance Plans Institute 2012 in Salt Lake City, UT.
Advertisement
Related to this article
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Preparing Practices for the Next Era of Hepatitis B Care
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
5